KATP channel Inhibitors
1 drugsAbout KATP channel
The ATP-sensitive potassium channel (KATP) regulates cellular excitability and insulin secretion by coupling cellular metabolism to electrical activity. It is formed by inward-rectifier potassium channel (Kir6.x) and sulfonylurea receptor (SURx) subunits.
Currently, there is no genetic evidence available linking KATP channels to specific diseases. However, their role in key physiological processes makes them attractive targets for therapeutic intervention.
Nateglinide, a small molecule approved in 2009, is the only FDA-approved drug targeting the KATP channel. It is used in the metabolic therapeutic area for managing type 2 diabetes.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Cesarean Section Complications with only 1 trials.
Top KATP channel Drugs
Only one company, Rising, has an approved drug targeting KATP channels.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target space.
KATP channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets KATP channel, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
KATP channel Clinical Trials 5 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 3 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
KATP channel Drug Approval Timeline (2009 - 2009)
The first and most recent drug approval for a KATP channel target was Nateglinide in 2009.
The lack of recent approvals suggests a saturated market or challenges in developing new KATP channel modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (6 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 6 clinical trials targeting KATP channel.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities